CytoMed Therapeutics Limited (GDTC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

CytoMed Therapeutics Limited (GDTC) closed at USD 0.86 on 2026-10-14, a change of -64 % over the past year, with a market capitalization of USD 10.38M.

CytoMed Therapeutics Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

CytoMed Therapeutics Limited key figures

Previous close

USD 0.86 (2026-10-14)

1-year change

-64 %

Market cap

USD 10.38M

Enterprise value

USD 9.81M

P/E ratio (trailing)

-3.78

P/E ratio (forward)

-5.80

EPS (trailing)

-0.23

EPS (forward)

-0.15

PEG ratio

n/a

Price to book

2.68

Revenue growth

-15.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.26

Employees

42

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About CytoMed Therapeutics Limited

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord-derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore; and Business and Research Collaboration Agreement with SunAct Cancer Institute Private Limited to conduct clinical trials for the GMP grade CTM-GDT. CytoMed Therapeutics Limited was incorporated in 2018 and is headquartered in Singapore.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for CytoMed Therapeutics Limited and compare it with other stocks.